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OBJECTIVE — Several second-generation antipsychotic (SGA) drugs have been associated
with weight gain, hyperglycemia, and dyslipidemia. We evaluated whether glucose and lipid
testing increased after the American Diabetes Association (ADA) consensus statement recom-
mending metabolic monitoring for SGA-treated patients.
RESEARCH DESIGN AND METHODS — Laboratory claims for serum glucose and
lipidtestingwereidentiﬁedforanincidentcohortof18,876adultsinitiatingSGAdrugsinaU.S.
commercial health plan (2001–2006) and a control group of 56,522 adults with diabetes not
receiving antipsychotics. Interrupted time-series models were used to estimate the effect of ADA
recommendationsonbaselineandannualtestingtrendsafteradjustingfordifferencesinage,sex,
mental health diagnoses, and cardiovascular risk using propensity score matching.
RESULTS — Mean baseline testing rates for SGA-treated patients during the study period
were 23% (glucose) and 8% (lipids). Among persistent users of SGA medication, annual testing
rates were 38% (glucose) and 23% (lipid). Before the ADA statement, screening rates for SGA-
treated patients were increasing (glucose: baseline 3.6% per year, annual 7.2% per year; lipid:
baseline 1.2% per year, annual 4.8% per year; P  0.001 for each trend). Increases were similar
to background testing trends in control subjects. The ADA statement was not associated with an
increase in screening rates.
CONCLUSIONS — In a commercially insured population, glucose and lipid testing for
SGA-treatedadultswasinfrequent.Agradualincreaseinscreeningratesoccurredoverthe6-year
period, but the changes were not temporally associated with the ADA statement. More effort is
needed to improve diabetes and dyslipidemia screening in these at-risk patients.
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A
dults with serious mental illness,
commonly treated with second-
generation antipsychotic (SGA)
drugs,haveuptotwo-times-greaterprev-
alence of type 2 diabetes, dyslipidemia,
hypertension, and obesity (1,2). Cardio-
vasculardiseaseistheleadingcontributor
tomortalityforadultswithseriousmental
illness (3–5), resulting in a decades less
life expectancy than the general popula-
tion (4). Increased risk for premature car-
diovascular mortality has been attributed
to lower socioeconomic status (6), physi-
calinactivityandpoordietarychoices(7),
obesity (8), greater smoking and sub-
stance abuse (7), adverse medication ef-
fects (1), and underutilization of primary
and secondary prevention (5). Unfortu-
nately, diabetes and cardiovascular risk is
often underrecognized (2) and under-
treated (9) in patients with mental illness.
SGA medication is a leading thera-
peutic class based on U.S. dollar sales
(Verispan; Vona). While SGA drugs were
initially approved for treatment of schizo-
phrenia,somearealsoapprovedforbipo-
lar disorder and more recently for use in
children. These agents are also used in
clinicalpracticefortreatmentofotherun-
approved conditions, such as insomnia
and anxiety. Following concerns about
medication-related metabolic risks
(10,11), the Food and Drug Administra-
tion (FDA) mandated class warnings
describing increased risk for severe hy-
perglycemiaanddiabetesandrequiredall
drugmanufacturerstomail“DearDoctor”
letters about the warning (12). The goal
wastoincreaseawarenessofthesignsand
symptomsofdiabetesandpromoteearlier
detection and treatment. In February
2004, the American Diabetes Association
(ADA) published a consensus statement
on antipsychotic drugs and obesity and
diabetes with the American Psychiatric
Association, the American Association of
Clinical Endocrinologists, and the North
American Association for the Study of
Obesity (13). The consensus statement
described the metabolic risks associated
with SGA drugs and recommended base-
line and ongoing assessment of fasting se-
rum glucose and lipid proﬁles in all
patients receiving these agents.
Metabolic screening in SGA-treated
patients is understudied. A recent report
(14) using Medicaid data indicated that
glucose and lipid testing were signiﬁ-
cantly underutilized in patients starting
SGA drug therapy before the consensus
statement. In the present study, we esti-
mated 6-year trends in outpatient serum
glucose and lipid testing rates using labo-
ratory claims for individuals starting SGA
drug therapy in a large, commercially in-
sured population. We evaluated whether
baseline and annual glucose and lipid
testing increased after the FDA warnings
and ADA consensus statement relative to
background-testing trends.
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METHODS— Administrative claims
data from four commercial health insur-
ance plans in the U.S., representing 9
million eligible members, were analyzed.
This study did not involve patient inter-
vention or use protected health informa-
tion and was therefore exempt from
institutional review board review. A co-
hort of 18,876 adults initiating one of six
widely used SGA drugs (aripiprazole, olan-
zapine, quetiapine, risperidone, or ziprasi-
done) during January 2001 through
December 2006 was identiﬁed from phar-
macy claims. A second control cohort of
56,522 adults with diabetes not receiving
SGA medication was identiﬁed by the
presence of a diabetes diagnosis in the
medical claims or a prescription claim for
an antihyperglycemic medication. The
purposeofthecontrolcohortwastocom-
pareglucoseandlipidtestingratesinSGA
users with background trends for the
same commercial plans and time period
in a group of patients indicated for meta-
bolic monitoring. We hypothesized that
glucose and lipid testing rates in adults
withdiabeteswouldnotbeaffectedbythe
antipsychotic warnings and ADA consen-
susstatementandcouldthereforeprovide
a control for other temporal trends on
testing rates within these commercial
plans. The index date for both cohorts
was the date of the ﬁrst qualifying pre-
scription or medical claim. Patients had
continuous eligibility for 1 year before
through 1 month after the index date for
baseline testing outcomes or through 1
yearaftertheindexdateforannualtesting
outcomes.
Assessment of glucose and lipid
testing
Glucosetestingwasidentiﬁedifamedical
claim with an American Medical Associa-
tion Current Procedural Terminology
(CPT) code for a metabolic or general
health panel (80048, 80050, and 80053)
or glucose-speciﬁc serum test (82947,
82948, 82950, and 82951) was present.
Lipid testing was identiﬁed if a CPT code
for a lipid panel (80061) or lipid-speciﬁc
serum test (82465, 84478, 83721,
83715, 83700, 83716, and 83701) was
present. Baseline was operationalized as
testing occurring 30 days before through
30daysaftertheindexdate.Annualmon-
itoring was operationalized as testing oc-
curring 31–365 days after the index date.
We recognize that glucose testing rates in
patients with diabetes will tend to under-
estimate absolute rates of glycemic moni-
toring, which routinely include the use of
glycated hemoglobin and home testing
with portable glucometers. For this rea-
son, we only compare temporal trends in
serum testing rates.
Patient characteristics
Disparities in diabetes care have been as-
sociated with mental disorders (9). Men-
tal health disorders were identiﬁed using
ICD-9 diagnosis codes ascertained from
medical claims in the 12 months before
the index date and classiﬁed into eight
categories using Clinical Classiﬁcations
Software (CCS) coding developed by the
Agency for Health Care Research and
Quality (15) (affective disorders, alcohol
and substance abuse, anxiety and person-
ality disorders, preadult disorders, senil-
ity, schizophrenia, other psychoses, and
other mental conditions).
Dyslipidemia, hypertension, and
heart disease are risk factors for type 2
diabetesandshouldtriggermorefrequent
screening.Toadjustfordifferencesincar-
diovascular risk between SGA users and
diabeticcontrolsubjects,individualswith
preexisting dyslipidemia, hypertension,
and heart disease were identiﬁed using
medical and pharmacy claims for 365
days before the index date. Dyslipidemia
wasdeﬁnedasadyslipidemiadiagnosisor
prescription for a cholesterol-lowering
drug. Hypertension was deﬁned as a hy-
pertension diagnosis or prescription for
an antihypertensive drug. Heart disease
was deﬁned as a diagnosis for acute myo-
cardial infarction, coronary atherosclero-
sis, pulmonary heart disease, or other
heart diseases using CCS classiﬁcation.
Age (at the index date) and sex are also
associated with the likelihood of diabetes
screening and were analyzed. Race/
ethnicity was unavailable for analysis.
Analytic strategy
A quasiexperimental design was used to
evaluate quarterly trends in baseline and
annual glucose testing rates for patients
initiating SGA drug therapy before versus
after publication of the ADA consensus
statement (ﬁrst quarter 2004) using seg-
mented time-series regression corrected
for ﬁrst-order autocorrelation (16). To
Table 1—Baseline patient characteristics in all patients
SGA cohort
Diabetes control
cohort P
Demographics
n 18,176 56,522
Female (%) 59.3 46.6 0.0001
Age-groups (years) (%)
20–29 13.2 4.7
30–39 19.0 13.8
40–49 25.2 24.4 0.0001
50–59 20.1 32.1
60–69 8.1 17.4
70–79 6.4 5.7
80–88 7.7 1.6
Mental health diagnoses (past 12 months)
Any of the following (%) 80.7 26.5 0.001
Affective disorders 49.3 2.5 0.0001
Anxiety disorders 29.2 2.9 0.0001
Alcohol and substance abuse 15.0 2.0 0.0001
Senility 10.4 0.4 0.0001
Other psychoses 9.4 0.1 0.0001
Preadult disorders 4.1 0.1 0.0001
Schizophrenia 3.4 0.1 0.0001
Other mental conditions 51.4 23.0 0.0001
Cardiovascular risk (past 12 months) (%)
Any of the following 51.0 69.0 0.0001
Hypertension 39.9 55.1 0.0001
Dyslipidemia 26.8 45.7 0.0001
Heart disease 4.7 3.6 0.02
Data are percentages. 
2 tests were conducted to test for differences in patient characteristics between SGA
users and adults with diabetes not receiving antipsychotic medication.
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characteristics when comparing temporal
trends between SGA users and diabetic
control subjects, a nearest neighbor 1:1
matched cohort of case and control sub-
jects was created for each quarter using
propensityscorematchingonpatientage,
sex, number of mental health disorders,
and presence of preexisting cardiovascu-
lar risk (dyslipidemia, hypertension, or
heartdisease)(17).Thisresultedinapro-
pensity-matched cohort of SGA-treated
patients and control subjects (n  8,759
pairs). The analysis of annual testing rates
was performed in persistent users of SGA
medication, who theoretically would be
at greater risk for developing long-term
metabolic side effects than patients re-
ceiving time-limited therapy. Persistent
SGAusershadamaximumgapintherapy
30 days during the initial 365 days of
therapy (18). Using the same propensity-
matching methods, a cohort of persistent
SGA-treated patients and matched con-
trol subjects was identiﬁed (n  2,218
pairs). Frequency of metabolic testing
among SGA users starting therapy in
2005, the most recent year after the ADA
statement with sufﬁcient follow-up to re-
port both baseline and annual rates, was
compared in patients with versus without
preexisting diabetes using 
2 tests. All
analyses used STATA version 10 (Stata,
College Station, TX).
RESULTS— Table 1 summarizes pa-
tient characteristics for adults starting
SGAtherapyandfordiabeticcontrolsub-
jects who did not receive antipsychotic
medication. Users of SGA medication
were younger than the average adult with
diabetes and more likely to have a re-
corded mental health diagnosis, (80.7 vs.
26.5%,P0.0001)butwerelesslikelyto
have identiﬁed dyslipidemia, hyperten-
sion,orheartdisease(51.0vs.69.0%,P
0.0001). Distribution of SGA drugs be-
fore versus after the consensus statement
was signiﬁcantly different (P  0.001)
(aripiprazole: 2 vs. 11%; olanzapine: 48
vs. 25%; quetiapine: 21 vs. 40%; ris-
peridone: 26 vs. 21%; and ziprasidone:
3 vs. 4%).
Mean baseline testing rates for SGA-
treated patients during the study period
were 23% (glucose) and 8% (lipids).
Trends in baseline testing for all SGA-
treated patients are presented in Fig. 1.
Baseline testing rates were increasing for
glucose (0.9% per quarter) and lipid test-
ing (0.4% per quarter) before the consen-
sus statement. There was not a signiﬁcant
increase,or“stepchange,”inbaselineglu-
cose testing during the quarter in which
the consensus statement was published
(P  0.80). The positive growth observed
inbaselineglucosetestingratesbeforethe
consensus statement was attenuated after
the statement, as evidenced by a negative
change in the slope, or “trend change,” of
0.8% per quarter (P  0.01). For base-
line lipid testing, there was a small posi-
tive step change during the quarter the
consensus statement was published
(1.5%, P  02); however, the positive
growth in baseline lipid testing was also
attenuated after the statement as evi-
denced by a negative trend change after
the statement (0.5% per quarter, P 
0.001).
Baseline testing trends for SGA-
treated patients were similar to back-
groundtestingtrendsinmatchedsubjects
with diabetes. Before the consensus state-
ment, baseline glucose testing was in-
creasing at similar rates in SGA patients
(0.8%perquarter[95%CI0.4–1.3])sim-
ilar to those in matched patients with di-
abetes (1.2% per quarter [0.6–1.8])
before. Baseline lipid testing rates were
also increasing before the statement, al-
though at a slightly slower rate for SGA
patients (0.5% per quarter [0.4–0.7])
compared with patients with diabetes
(1.1% per quarter [0.8 – 1.4]). After the
statement,baselinetestingtrendswereno
different between SGA-treated patients
and matched adults with diabetes (glu-
cose, P  0.68; lipids, P  0.35), as mea-
sured by trends in the ratio of testing
rates.
Among persistent users of SGA med-
ication, mean annual testing rates during
the study period were 38% (glucose) and
23% (lipids). Trends in annual metabolic
testing for SGA-treated patients are pre-
sented in Fig. 2. Rates of annual glucose
testingwereincreasingbeforetheconsen-
Figure 1—Trends in baseline serum glucose (A) and lipids (B) laboratory testing in SGA-treated
adults. n  18,876 adults initiating SGA drug therapy.
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was no step change or increase in testing
ratesduringthequarterthestatementwas
published (P  0.68), and testing trends
didnotchangeasaresultofthestatement
(P  0.32). Annual lipid testing rates
were also increasing before the consensus
statementatarateof1.2%perquarter.As
with annual glucose testing, there was no
step change in annual lipid testing rates
(P  0.32), and lipid testing trends did
not change as a result of the statement
(P  0.64).
AnnualtestingtrendsamongSGApa-
tients were consistent with background
testing trends in matched subjects with
diabetes. Before the statement, annual
glucose testing was increasing at similar
rates for both SGA patients (1.8% per
quarter [95% CI 1.3–2.2]) and patients
with diabetes (1.2% per quarter [1.0–
1.5]). Prestatement trends were also sim-
ilar for annual lipid testing in SGA
patients (1.2% per quarter [0.8–1.5]),
compared with patients with diabetes
(1.1% per quarter [0.9–1.3]). After the
statement, annual testing trends were no
different between SGA-treated patients
and adults with diabetes (glucose, P 
0.92; lipids, P  0.26) as measured by
trends in the ratio of testing rates.
Table 2 summarizes the frequency of
baseline and annual serum glucose and
lipid testing among adults initiating SGA
drug therapy in 2005. Baseline glucose
testing occurred in 25% of SGA-utilizing
patients and baseline lipid testing oc-
curred in 9% of patients. Approximately
10% of patients had identiﬁed diabetes.
Overall,baselinetestingwashigherifpre-
existing diabetes was identiﬁed (glucose:
36 vs. 24%, P  0.001; lipids: 16 vs. 8%,
P  0.001). Among SGA patients with
therapy persistent for 1 year, annual glu-
cose testing occurred in 49% of patients
and annual lipid testing in 31% of pa-
tients. Annual rates of testing among per-
sistent SGA users were not signiﬁcantly
differentbetweenadultswithandwithout
identiﬁed diabetes. Baseline and annual
testing rates were not signiﬁcantly differ-
ent in men versus women (data not
shown).
CONCLUSIONS — This population-
based study examined the impact of the
ADA consensus statement on baseline
and annual testing of serum glucose and
lipids for SGA-treated adults within a
commercially insured population. We
found that baseline and annual glucose
and lipid testing rates for SGA-treated pa-
tients increased between 2001 and 2006.
However, the rising trends in testing ap-
pear to be attributable to increases ob-
served in background testing trends
ratherthanaspeciﬁcresponsetotheADA
consensus recommendations. Impor-
tantly,metabolictestingremainedsubop-
timal for SGA users. By the end of 2005,
75% of SGA users received no baseline
glucosetestingand90%receivednobase-
line lipids assessment. Annual rates of
testing were more favorable; nonethe-
less, half of the SGA-treated adults re-
ceived no glucose testing and two-thirds
no lipid testing in the year following drug
initiation.
This study identiﬁed metabolic test-
ing based on laboratory claims from mul-
tiple outpatient settings within the
commercial health plan. However, it was
not possible to conﬁrm whether tests
were ordered by, or were available to, cli-
niciansresponsibleforSGAtreatmentde-
cision making. It is almost certain that
some proportion of testing was per-
formed for purposes other than the rec-
ommended evaluation of SGA effects on
glucose or lipid levels. Therefore, the ab-
soluteratesofglucoseandlipidtestingwe
observed for SGA-treated patients are
likely overestimates of actual metabolic
monitoring related to SGA treatment.
Althoughthisretrospectivestudywas
not able to look into the reasons why lab-
oratory screening did not increase after
the ADA consensus statement, we might
speculate on some possible explanations.
On one hand, the results are not surpris-
ing because typically half of physicians
follow any given clinical guideline (19).
Adoption of other monitoring recom-
mendations following drug warnings has
Figure2—TrendsinannualserumglucoseandlipidslaboratorytestinginpersistentusersofSGA
drug therapy. n  3,140 adults initiating SGA drug therapy who were therapy persistent for 1
year.
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adherence to evidence-based treatment
recommendations have been studied, in-
cluding low awareness, lack of medical
consensus, low self-efﬁcacy to enact
change, and failure to overcome the iner-
tia of previous practice (21). Another ex-
planation offered is that physicians treat
guidelines more as options as opposed to
true standards and professional organiza-
tions,suchastheADAandAmericanPsy-
chiatric Association, cannot enforce
adherence (19).
On the other hand, the low rates of se-
rum testing observed in this study popula-
tion are surprising given high awareness
among psychiatrists of the metabolic risks
associated with SGA medication and strong
agreement on the need to screen and mon-
itor patients (22,23). After the consensus
statement, 60–80% of psychiatrists re-
ported monitoring glucose and lipid levels
at regular intervals (22,23). It could be that
surveyed psychiatrists were not representa-
tive of all SGA prescribers. Alternatively,
poor patient follow-through between the
physician ordering the lab and the patient
getting blood drawn may be occurring.
More research is needed to determine why
thegapexistsbetweenreportedmonitoring
behaviorandobservedserumtestingbefore
improvements can be made in diabetes and
dyslipidemia screening and ongoing moni-
toring for these at-risk patients.
The ADA consensus statement (13)
and subsequent published research (1)
have acknowledged that not all antipsy-
chotics have the same metabolic risk
proﬁle; for example, olanzapine, in par-
ticular, has been cited as having a high
risk for weight gain, metabolic distur-
bances, and dyslipidemia (1,13). As an
alternative to greater vigilance in meta-
bolic monitoring, some physicians may
have started avoiding drugs with greater
metabolic risk. The ﬁnding that olanzap-
ine’s share of new starts dropped from 48
to 25% after the statement is consistent
with this hypothesis. Nevertheless, the
FDA class warnings (14) and the ADA
consensus statement (15) call for meta-
bolic monitoring in all patients regardless
of which SGA medication they are
receiving.
Theresultsofthisresearcharesubject
to limitations. Because we relied on ad-
ministrative claims records, we could not
evaluate the impact of the consensus
statement on unbilled metabolic screen-
ing(e.g.,familyhistoryofdiabetes,height
and body weight, or waist circumference)
or testing occurring during a hospital ad-
mission. Caution should also be applied
in generalizing ﬁndings to all patients ini-
tiating antipsychotic medications, for ex-
ample Medicaid clients. In addition,
anecdotal reports suggest some local
mental health treatment centers have
been successful in increasing rates of glu-
cose and lipid testing using incentives
(e.g.,ﬁnancialcompensationtotheorder-
ing clinician) or disincentives (e.g., shar-
ingindividualclinicianperformancerates
among a peer group).
In summary, despite psychiatrist
awarenessofmetabolicriskandhighrates
of self-reported screening, we found little
evidence that patients starting SGA med-
ication typically receive serum glucose
and lipid testing. Although a gradual in-
crease in screening rates occurred over
the 6-year period, publication of the ADA
consensus statement on SGA drugs and
diabetes risk was not associated with an
increaseinaboratorytestingrates.Results
from this study of commercially insured
patients suggest a considerable gap re-
mains between clinical practice and ADA
recommendations for routine metabolic
monitoring in a population at increased
risk for diabetes and cardiovascular dis-
ease. More effort is needed to ensure that
patientsreceivingSGAdrugsarescreened
for diabetes and dyslipidemia.
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